Quick Answer
Foghorn Therapeutics Inc. reported Long Term Debt of $0.00 for the year ending 2021.
- Foghorn Therapeutics Inc. showed a decrease of -100.0% in Long Term Debt from 2020 to 2021.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2022.
- XBRL data for this metric is available from 2019 to 2021 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $8.80 million | Q4 2020: $19.65 million | Q1 2021: $19.74 million | Q2 2021: $19.83 million | Q3 2021: $19.91 million.
- Over the full 3 years of available data (2019 to 2021), Foghorn Therapeutics Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2021: $0.00 | Fiscal year 2020: $19.65 million | Fiscal year 2019: $10.96 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: